Emergent expansion of clinical epigenetics in patients with cardiovascular diseases
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved..
PURPOSE OF REVIEW: Cardiovascular diseases (CVDs) are typically caused by multifactorial events including mutations in a large number of genes. Epigenetic-derived modifications in the cells are normal but can be amended by aging, lifestyle, and exposure to toxic substances. Major epigenetic modifications are DNA methylation, histone modification, chromatin remodeling as well as the noncoding RNAs. These pivotal players are involved in the epigenetic-induced modifications observed during CVDs. Nevertheless, despite impressive efforts capitalized in epigenetic research in the last 50 years, clinical applications are still not satisfactory.
RECENT FINDINGS: Briefly, we present some of the recent steps forward in the epigenetic studies of CVDs. There is an increased appreciation for the contribution of epigenetic alterations in the development of CVDs. Now, we have novel epigenetic biomarkers and therapeutic trials with the use of statins, metformin, and some compounds affecting epigenetic pathways including a BET inhibitor apabetalone. The new knowledge of epigenetic regulation is also discussed in the light of precision medicine of CVDs.
SUMMARY: Epigenetic studies of CVDs have the promise to yield both mechanistic insights as well as adjunct treatments (repurposed drugs and apabetalone). The overall concept of precision medicine is not widely recognized in routine medical practice and the so-called reductionist approach remains the most used way to treat CVD patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Current opinion in cardiology - 36(2021), 3 vom: 01. Mai, Seite 295-300 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Napoli, Claudio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.04.2021 Date Revised 08.05.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/HCO.0000000000000843 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321643704 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321643704 | ||
| 003 | DE-627 | ||
| 005 | 20231225180315.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HCO.0000000000000843 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321643704 | ||
| 035 | |a (NLM)33605616 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Napoli, Claudio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emergent expansion of clinical epigenetics in patients with cardiovascular diseases |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2021 | ||
| 500 | |a Date Revised 08.05.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a PURPOSE OF REVIEW: Cardiovascular diseases (CVDs) are typically caused by multifactorial events including mutations in a large number of genes. Epigenetic-derived modifications in the cells are normal but can be amended by aging, lifestyle, and exposure to toxic substances. Major epigenetic modifications are DNA methylation, histone modification, chromatin remodeling as well as the noncoding RNAs. These pivotal players are involved in the epigenetic-induced modifications observed during CVDs. Nevertheless, despite impressive efforts capitalized in epigenetic research in the last 50 years, clinical applications are still not satisfactory | ||
| 520 | |a RECENT FINDINGS: Briefly, we present some of the recent steps forward in the epigenetic studies of CVDs. There is an increased appreciation for the contribution of epigenetic alterations in the development of CVDs. Now, we have novel epigenetic biomarkers and therapeutic trials with the use of statins, metformin, and some compounds affecting epigenetic pathways including a BET inhibitor apabetalone. The new knowledge of epigenetic regulation is also discussed in the light of precision medicine of CVDs | ||
| 520 | |a SUMMARY: Epigenetic studies of CVDs have the promise to yield both mechanistic insights as well as adjunct treatments (repurposed drugs and apabetalone). The overall concept of precision medicine is not widely recognized in routine medical practice and the so-called reductionist approach remains the most used way to treat CVD patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a RNA, Untranslated |2 NLM | |
| 700 | 1 | |a Coscioni, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a de Nigris, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Donatelli, Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in cardiology |d 1988 |g 36(2021), 3 vom: 01. Mai, Seite 295-300 |w (DE-627)NLM07472701X |x 1531-7080 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:3 |g day:01 |g month:05 |g pages:295-300 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HCO.0000000000000843 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 3 |b 01 |c 05 |h 295-300 | ||